CABC faculty Wolfgang Liedktke discovers and tests new class of pain releivers.

New research  from Center on Addiction & Behavior Change (CABC) faculty Wolfgang Liedktke [EDIT: Link no longer exists] and his collaborators has revealed a potential new class of small-molecule drugs that simultaneously block two sought-after targets in the treatment of pain. The proof-of-concept experiments, published June 1 in Scientific Reports, could lead to the development of a new drug to treat conditions including skin irritation and itching, headaches, jaw pain, and abdominal pain stemming from the pancreas and colon.

Image